medigraphic.com
ISSN 0016-3813 (Impreso)

2015, Número 6

<< Anterior Siguiente >>

Gac Med Mex 2015; 151 (6)


Susceptibilidad de generar drepanocitos en muestras de pacientes heterocigotos para hemoglobina S (rasgo falciforme) que padecen diabetes mellitus tipo 2

Díaz-Piedra P, Cervantes-Villagrana AR, Ramos-Jiménez R, Presno-Bernal JM, Cervantes-Villagrana RD

Idioma: Español
Referencias bibliográficas: 38
Paginas: 757-763
Archivo PDF: 105.47 Kb.


RESUMEN

La hemoglobina S (HbS) es una proteína anormal que produce cambios morfológicos en los eritrocitos en condiciones de bajo oxígeno. En México se reporta hasta un 13.7% de la población con la mutación en un alelo considerada asintomática (rasgo falciforme). El rasgo falciforme y diabetes mellitus (DM) se presentan juntas en más de 1 millón de pacientes a nivel mundial. Este binomio posiblemente potencia las alteraciones microvasculares en retinopatía y síndrome torácico agudo. El objetivo de este trabajo fue evaluar la inducción de drepanocitos en muestras de pacientes diabéticos con rasgo falciforme para identificar parámetros alterados de la serie roja. Para ello, obtuvimos muestras de pacientes diabéticos para determinar hemoglobina glucosilada A1c (HbA1c) y HbS, además de biometría para analizar los datos eritrocitarios. Encontramos que los pacientes diabéticos masculinos con mayor edad fueron susceptibles a generar drepanocitos y correlaciona con un menor conteo de eritrocitos (RBC) y un incremento del volumen corpuscular medio (MCV). En muestras de pacientes diabéticas femeninas no se presentaron diferencias. Nosotros concluimos que las muestras de pacientes con rasgo falciforme y diabetes pueden generar drepanocitos en frotis; y en varones corresponden a individuos con mayor edad, un menor RBC y un mayor MCV como parámetros de susceptibilidad.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Snell FM. Facilitated transport of oxygen through solutions of hemoglobin. J Theor Biol. 1965;8:469-79.

  2. Macchiato MF, Tramontano A. VARIANT: a store and retrieval system for human haemoglobin variants. Comput Methods Programs Biomed. 1990;31:113-4.

  3. Zeng Y, Huang S. The studies of hemoglobinopathies and thalassemia in China--the experiences in Shanghai Institute of Medical Genetics. Clin Chim Acta. 2001;313:107-11.

  4. Lorey FW, Arnopp J, Cunningham GC. Distribution of hemoglobinopathy variants by ethnicity in a multiethnic state. Genet Epidemiol. 1996;13:501-12.

  5. Penaloza-Espinosa RI, Buentello-Malo L, Hernandez-Maya MA, et al. Hemoglobin S frequency in five Mexican populations and its importance in public health. Salud Publica Mex. 2008;50:325-9.

  6. R HG. Hemoglobin Disorders. En: Nelson textbook of pediatrics; Elsevier; 2000, pp.

  7. Wajcman H, Prehu C, Bardakdjian-Michau J, et al. Abnormal hemoglobins: laboratory methods. Hemoglobin. 2001;25:169-81.

  8. Dong C, Chadwick RS, Schechter AN. Influence of sickle hemoglobin polymerization and membrane properties on deformability of sickle erythrocytes in the microcirculation. Biophys J. 1992;63:774-83.

  9. Rodgers GP, Schechter AN, Noguchi CT, et al. Periodic microcirculatory flow in patients with sickle-cell disease. N Engl J Med. 1984;311: 1534-8.

  10. Chien S, Kaperonis AA, King RG, et al. Rheology of sickle cells and its role in microcirculatory dynamics. Prog Clin Biol Res. 1987;240:151-65.

  11. Connes P, Tripette J, Chalabi T, et al. Effects of strenuous exercise on blood coagulation activity in sickle cell trait carriers. Clin Hemorheol Microcirc. 2008;38:13-21.

  12. Abu-Zeid YA, Theander TG, Abdulhadi NH, et al. Modulation of the cellular immune response during Plasmodium falciparum infections in sickle cell trait individuals. Clin Exp Immunol. 1992;88:112-8.

  13. Juncos JP, Grande JP, Croatt AJ, et al. Early and prominent alterations in hemodynamics, signaling, and gene expression following renal ischemia in sickle cell disease. Am J Physiol Renal Physiol. 2010;298: F892-9.

  14. Ali Z, Troncoso JC, Fowler DR. Recurrent cerebral venous thrombosis associated with heterozygote methylenetetrahydrofolate reductase CT mutation and sickle cell trait without homocysteinemia: An autopsy case report and review of literature. Forensic Sci Int; 2014.

  15. Vigneri R. Diabetes: diabetes therapy and cancer risk. Nat Rev Endocrinol. 2009;5:651-2.

  16. Pauer J, Fek A, Buday B, et al. Metabolic alteration in healthy men with first degree type 2 diabetic relatives. Orv Hetil. 2013;154:178-86.

  17. Klotzbucher E. Glucagon hyperglycemia and disordered insulin utilization in diabetes mellitus in man. Dtsch Gesundheitsw. 1952;7:1487.

  18. Matkovics B, Varga SI, Szabo L, et al. The effect of diabetes on the activities of the peroxide metabolism enzymes. Horm Metab Res. 1982;14:77-9.

  19. Lobner K, Fuchtenbusch M. Inflammation and diabetes. MMW Fortschr Med. 2004;146:32-3, 5-6.

  20. Sibireva OF, Kaliuzhin VV, Urazova OI, et al. The biochemical markers of endothelium dysfunction in patients with diabetic nephropathy. Klin Lab Diagn. 2012;8-11.

  21. Vazzana N, Ranalli P, Cuccurullo C, et al. Diabetes mellitus and thrombosis. Thromb Res. 2012;129:371-7.

  22. Gabbay IE, Gabbay M, Gabbay U. Diabetic foot cellular hypoxia may be due to capillary shunting--a novel hypothesis. Med Hypotheses. 2014;82:57-9.

  23. Levitt NS. Diabetes in Africa: epidemiology, management and healthcare challenges. Heart. 2008;94:1376-82.

  24. Tsaras G, Owusu-Ansah A, Boateng FO, et al. Complications associated with sickle cell trait: a brief narrative review. Am J Med. 2009;122:507-12.

  25. Franch-Nadal J, Roura-Olmeda P, Benito-Badorrey B, et al. Metabolic control and cardiovascular risk factors in type 2 diabetes mellitus patients according to diabetes duration. Fam Pract. 2014.

  26. Keren DF, Hedstrom D, Gulbranson R, et al. Comparison of Sebia Capillarys capillary electrophoresis with the Primus high-pressure liquid chromatography in the evaluation of hemoglobinopathies. Am J Clin Pathol. 2008;130:824-31.

  27. Maniatis A, Frieman B, Bertles JF. Increased expression in erythrocytes ii antigens in sickle cell disease and sickle cell trait. Vox Sang. 1977; 33:29-36.

  28. Bain BJ. Haemoglobinopathy diagnosis: algorithms, lessons and pitfalls. Blood Rev. 2011;25:205-13.

  29. Ama V, Kengne AP, Nansseu NJ, et al. Would sickle cell trait influence the metabolic control in sub-Saharan individuals with type 2 diabetes? Diabet Med. 2012;29:e334-7.

  30. Bleyer AJ, Vidya S, Sujata L, et al. The impact of sickle cell trait on glycated haemoglobin in diabetes mellitus. Diabet Med. 2010;27:1012-6.

  31. Aleyassine H. Glycosylation of hemoglobin S and hemoglobin C. Clin Chem. 1980;26:526-7.

  32. Abdella PM, Ritchey JM, et al. Glycosylation of hemoglobin S by reducing sugars and its effect on gelation. Biochim Biophys Acta. 1977;490:462-70.

  33. Abraham EC, Elseweidy MM. Non-enzymatic glycosylation influences Hb S polymerization. Hemoglobin. 1986;10;173-83.

  34. Abraham EC, Cameron BF, Abraham A, et al. Glycosylated hemoglobins in heterozygotes and homozygotes for hemoglobin C with or without diabetes. J Lab Clin Med. 1984;104:602-9.

  35. Ruiz-Reyes G. Fundamentos de Hematología. Panamericana; 1998. pp 31-44.

  36. Kaul DK, Liu XD. Rate of deoxygenation modulates rheologic behavior of sickle red blood cells at a given mean corpuscular hemoglobin concentration. Clin Hemorheol Microcirc. 1999;21;125-35.

  37. Ajayi AA, Kolawole BA. Sickle cell trait and gender influence type 2 diabetic complications in African patients. Eur J Intern Med. 2004;15:312-5.

  38. Kolawole BA, Ajayi AA. Prognostic indices for intra-hospital mortality in Nigerian diabetic NIDDM patients. Role of gender and hypertension. J Diabetes Complications. 2000;14:84-9.




2020     |     www.medigraphic.com